Robert Hyde
Co-Founder and CTO
Vet Vision AI
With private funds becoming more selective, this closed-door roundtable brings together leading animal health investors to explore where confidence is quietly building. We will debate how investors and corporates can align and structure strategic alliances efficiently, to accelerate next generation of breakthrough innovations before they peak, creating tangible value for the animal health ecosystem and the world at large.
Eduardo Pontes
Head of External Evaluation
Ceva
Ceva
Website: www.ceva.com/en
It’s estimated that a staggering 75% of all emerging human infectious diseases originate from animals and birds. These zoonoses, as they’re known, are what compel Ceva to innovate – to succeed in the fight against the likes of avian flu, brucellosis and Q-fever. They’re one of the driving forces behind our vision: ‘Together, beyond animal health’.
Ceva works with welfare and social programmes around the world to bring this vision to life – anywhere our products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
They’re truly global, based in 46 countries and working across more than 110. We have 12 R&D centres, 25 production sites and more than 5000 employees worldwide.
Key takeaways will include:
- The importance of finding the right partner(s) and strategies for doing so
- Strategies for tailoring a pitch for strategic partners
- Insights into how MAH deploys its transaction toolkit to enable bespoke partnering
- Discussion on how the combination of venturing and traditional R&D is used to drive innovation in MAH’s portfolio
- Insights into how strategic partnering can extend financing runways
- Deeper understanding of the convergence of high tech and biotech in the lab, clinic and on the farm
Jim McIntyre
Head of Global Business Development
Merck Animal Health
Peter Opdam
Director, Business Development – Europe
Merck Animal Health
Stuart Junor
Director, Business Development Europe
Merck Animal Health
MSD Animal Health
Website: www.msd-animal-health.com
At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and X (formerly Twitter).